NCT02465060 ACTIVE NOT RECRUITING Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
NCT05828511 RECRUITING A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Regeneron Pharmaceuticals
NCT06993675 RECRUITING Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Noffar Bar
NCT05231629 RECRUITING Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
University of Alabama at Birmingham
NCT06179888 RECRUITING Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
NCT06169215 ACTIVE NOT RECRUITING Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
NCT05497804 ACTIVE NOT RECRUITING Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
NCT06390865 ACTIVE NOT RECRUITING Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
NCT05002816 ACTIVE NOT RECRUITING Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
NCT06948084 NOT YET RECRUITING Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
NCT06400225 ACTIVE NOT RECRUITING Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
National Cancer Institute (NCI)
NCT07463807 NOT YET RECRUITING Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
NCT06385496 ACTIVE NOT RECRUITING Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
NCT06066359 RECRUITING Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
M.D. Anderson Cancer Center
NCT05514990 ACTIVE NOT RECRUITING Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
NCT05669989 ACTIVE NOT RECRUITING International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
NCT05060627 ACTIVE NOT RECRUITING Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
PETHEMA Foundation
NCT05849610 ACTIVE NOT RECRUITING Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
PETHEMA Foundation
NCT04973605 RECRUITING A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
NCT06400251 ACTIVE NOT RECRUITING Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
National Cancer Institute (NCI)
NCT07116616 RECRUITING A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
NCT00871013 ACTIVE NOT RECRUITING Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
University of Arkansas
NCT06500884 RECRUITING A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Janssen Research & Development, LLC
NCT05527340 ACTIVE NOT RECRUITING Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
PETHEMA Foundation
NCT07266441 RECRUITING A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
NCT04439110 ACTIVE NOT RECRUITING Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
NCT03412877 RECRUITING Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT06577025 ACTIVE NOT RECRUITING A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Janssen Research & Development, LLC
NCT06550895 ACTIVE NOT RECRUITING A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Janssen Research & Development, LLC
NCT07149857 RECRUITING A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
NCT06103838 RECRUITING 18F-Fluciclovine PET/CT in Multiple Myeloma
National Cancer Institute (NCI)
NCT04439279 ACTIVE NOT RECRUITING Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
NCT05535244 ACTIVE NOT RECRUITING A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Hoffmann-La Roche
NCT04439266 ACTIVE NOT RECRUITING Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
NCT04439331 ACTIVE NOT RECRUITING Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
NCT04439344 ACTIVE NOT RECRUITING Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
NCT05850234 RECRUITING AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
AstraZeneca
NCT06106945 RECRUITING AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca
NCT07567014 NOT YET RECRUITING Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NYU Langone Health
NCT04126200 ACTIVE NOT RECRUITING Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
NCT05092451 RECRUITING Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT07084896 ACTIVE NOT RECRUITING Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
NCT06357988 ACTIVE NOT RECRUITING Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
NCT04439175 ACTIVE NOT RECRUITING Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
NCT04439123 ACTIVE NOT RECRUITING Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
National Cancer Institute (NCI)
NCT06400238 ACTIVE NOT RECRUITING Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
NCT05490771 ACTIVE NOT RECRUITING Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
NCT03556332 ACTIVE NOT RECRUITING A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT02727803 RECRUITING Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
NCT04888741 RECRUITING Methods of T Cell Depletion Trial (MoTD)
University of Birmingham
NCT06390852 ACTIVE NOT RECRUITING Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
National Cancer Institute (NCI)
NCT04439227 ACTIVE NOT RECRUITING Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
NCT05583617 RECRUITING A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Hoffmann-La Roche
NCT04508790 RECRUITING Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
NCT02343042 ACTIVE NOT RECRUITING Selinexor and Backbone Treatments of Multiple Myeloma Patients
Karyopharm Therapeutics Inc
NCT06360575 ACTIVE NOT RECRUITING Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
NCT07009899 NOT YET RECRUITING BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
Medical College of Wisconsin
NCT04933539 ACTIVE NOT RECRUITING Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
NCT05014646 ACTIVE NOT RECRUITING Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
City of Hope Medical Center
NCT04653246 ACTIVE NOT RECRUITING Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Jacob Laubach, MD
NCT07227311 RECRUITING A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
NCT04439136 ACTIVE NOT RECRUITING Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
National Cancer Institute (NCI)
NCT04439253 ACTIVE NOT RECRUITING Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
NCT06390826 ACTIVE NOT RECRUITING Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
NCT06421675 RECRUITING Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG)
NCT06429150 RECRUITING Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
NCT06679829 RECRUITING A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT06974786 RECRUITING Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
SCRI Development Innovations, LLC
NCT06385483 ACTIVE NOT RECRUITING Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
NCT07096778 RECRUITING Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
CellCentric Ltd.
NCT05972135 RECRUITING Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
NCT05392946 ACTIVE NOT RECRUITING Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
NCT03761108 RECRUITING Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Regeneron Pharmaceuticals
NCT05969860 RECRUITING At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT04561492 ACTIVE NOT RECRUITING Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
Nantes University Hospital
NCT04166565 ACTIVE NOT RECRUITING Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
Stichting European Myeloma Network
NCT05909059 RECRUITING CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
NCT04776395 RECRUITING Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
NCT06523621 ACTIVE NOT RECRUITING Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Wake Forest University Health Sciences
NCT06083922 RECRUITING A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
NCT04822337 ACTIVE NOT RECRUITING Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
NCT05336383 RECRUITING Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT07455851 RECRUITING A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
NCT03763162 ACTIVE NOT RECRUITING Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT07107529 RECRUITING Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
NCT05434689 ACTIVE NOT RECRUITING COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
University of Alabama at Birmingham
NCT02420860 ACTIVE NOT RECRUITING Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
NCT02960555 ACTIVE NOT RECRUITING Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
NCT07382739 RECRUITING A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
M.D. Anderson Cancer Center
NCT03192397 ACTIVE NOT RECRUITING Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT04439292 ACTIVE NOT RECRUITING Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
NCT06308822 ACTIVE NOT RECRUITING Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
NCT04439318 ACTIVE NOT RECRUITING Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
NCT07523555 RECRUITING Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech
NCT06483100 RECRUITING Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine
NCT06669247 RECRUITING A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
NCT03500445 ACTIVE NOT RECRUITING Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
NCT05955508 ACTIVE NOT RECRUITING A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Regeneron Pharmaceuticals
NCT04133636 ACTIVE NOT RECRUITING A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Janssen Research & Development, LLC
NCT06303167 ACTIVE NOT RECRUITING Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
NCT04439357 ACTIVE NOT RECRUITING Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
NCT06140524 RECRUITING A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Regeneron Pharmaceuticals
NCT01054196 ACTIVE NOT RECRUITING Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Weill Medical College of Cornell University
NCT04925193 ACTIVE NOT RECRUITING Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
University of Colorado, Denver
NCT06536413 RECRUITING ATRA and Carfilzomib in Plasma Cell Myeloma Patients
The Methodist Hospital Research Institute
NCT07510100 NOT YET RECRUITING Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
NCT07509086 RECRUITING IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
The First Hospital of Jilin University
NCT02693535 RECRUITING TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
American Society of Clinical Oncology
NCT05393804 ACTIVE NOT RECRUITING A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT04876248 ACTIVE NOT RECRUITING Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Roswell Park Cancer Institute
NCT04643002 RECRUITING Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Sanofi
NCT07181941 RECRUITING Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
NCT03297606 RECRUITING Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Canadian Cancer Trials Group
NCT04835129 ACTIVE NOT RECRUITING Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
NCT03236428 ACTIVE NOT RECRUITING Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
NCT06232044 RECRUITING Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
NCT07489534 RECRUITING Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Daihong Liu
NCT04268498 ACTIVE NOT RECRUITING A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
University of Miami
NCT04988555 RECRUITING A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
NCT07479979 RECRUITING Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Natalie Callander
NCT07292272 RECRUITING Halt Aging in Survivors of Blood Cancers
University of Nebraska
NCT04680468 ACTIVE NOT RECRUITING Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
University of Pennsylvania
NCT01297764 ACTIVE NOT RECRUITING A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Hackensack Meridian Health
NCT02773030 ACTIVE NOT RECRUITING A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
NCT07485647 NOT YET RECRUITING Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Eden Biltibo
NCT05405387 RECRUITING Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
University of Utah
NCT06357975 ACTIVE NOT RECRUITING Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
NCT05272826 RECRUITING Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Canadian Myeloma Research Group
NCT02952508 ACTIVE NOT RECRUITING Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences, Inc.
NCT07477912 RECRUITING Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
NCT06353022 ACTIVE NOT RECRUITING Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
Nantes University Hospital
NCT05690984 ACTIVE NOT RECRUITING Elimination of Minimal Residual Disease After Transplant
Medical College of Wisconsin
NCT04883242 ACTIVE NOT RECRUITING Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
NCT06138275 RECRUITING Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital
NCT06832865 RECRUITING ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
NCT05767359 ACTIVE NOT RECRUITING CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
NCT07284758 RECRUITING A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc.
NCT04151667 ACTIVE NOT RECRUITING Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT06976476 RECRUITING Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Memorial Sloan Kettering Cancer Center
NCT05896228 RECRUITING Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Benjamin T Diamond, MD
NCT07454187 NOT YET RECRUITING To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.
NCT07454382 RECRUITING A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT05091372 RECRUITING Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
NCT04094961 ACTIVE NOT RECRUITING Ixazomib + Pomalidomide + Dexamethasone In MM
Omar Nadeem, MD
NCT04802356 ACTIVE NOT RECRUITING Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
PETHEMA Foundation
NCT04656951 ACTIVE NOT RECRUITING Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
University of Cologne
NCT06066346 RECRUITING A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
NCT07029776 NOT YET RECRUITING MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
NCT07169500 RECRUITING Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
NCT03589222 ACTIVE NOT RECRUITING SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
PETHEMA Foundation
NCT06235229 RECRUITING A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd.
NCT04764942 ACTIVE NOT RECRUITING Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
NCT07336472 NOT YET RECRUITING A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Fortvita Biologics (USA)Inc.
NCT06100237 RECRUITING Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Carl Ola Landgren, MD, PhD
NCT06356571 RECRUITING A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Sanofi
NCT05344833 RECRUITING Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
University of Illinois at Chicago
NCT06953960 RECRUITING A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
NCT05530421 RECRUITING Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
University of Miami
NCT06711705 RECRUITING Elranatamab in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
NCT07421856 NOT YET RECRUITING Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Hebei Senlang Biotechnology Inc., Ltd.
NCT06207799 RECRUITING Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
NCT07410494 RECRUITING Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT05199311 RECRUITING Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
NCT06105554 RECRUITING Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT06892522 RECRUITING A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
NCT02861417 ACTIVE NOT RECRUITING Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT07409454 NOT YET RECRUITING MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT05396885 ACTIVE NOT RECRUITING Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Kite, A Gilead Company
NCT04977024 ACTIVE NOT RECRUITING SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
NCT07099391 RECRUITING A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT06015542 RECRUITING Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Thomas Lund
NCT06297226 RECRUITING Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT04850846 ACTIVE NOT RECRUITING Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
NCT03933735 ACTIVE NOT RECRUITING A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT06940297 RECRUITING Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT05874193 NOT YET RECRUITING A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Cristiana Costa Chase, DO
NCT05847569 RECRUITING Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Mayo Clinic
NCT04113018 ACTIVE NOT RECRUITING Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Wake Forest University Health Sciences
NCT06988488 RECRUITING A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
NCT04414475 RECRUITING A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Karyopharm Therapeutics Inc
NCT04430894 ACTIVE NOT RECRUITING KRDI in Transplant-Eligible MM
Massachusetts General Hospital
NCT04240054 RECRUITING Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Medical College of Wisconsin
NCT05714839 RECRUITING A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
GlaxoSmithKline
NCT02718833 ACTIVE NOT RECRUITING A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
NCT04586426 ACTIVE NOT RECRUITING A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
NCT07348393 NOT YET RECRUITING A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Assistance Publique - Hôpitaux de Paris
NCT05922501 RECRUITING Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
NCT06627751 RECRUITING Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Roswell Park Cancer Institute
NCT03030261 ACTIVE NOT RECRUITING Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Washington University School of Medicine
NCT06910124 RECRUITING Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Dickran Kazandjian, MD
NCT01746849 ACTIVE NOT RECRUITING Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT07312188 RECRUITING A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
NCT04991103 RECRUITING Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
NCT05704049 ACTIVE NOT RECRUITING A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Sanofi
NCT05695508 RECRUITING GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
University of Heidelberg Medical Center
NCT05130827 ACTIVE NOT RECRUITING Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Memorial Sloan Kettering Cancer Center
NCT07285044 RECRUITING The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT05789303 RECRUITING Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
NCT04850599 ACTIVE NOT RECRUITING Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
NCT06827860 RECRUITING Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Larysa Sanchez
NCT05801939 ACTIVE NOT RECRUITING Cevostamab Following CAR T Cell Therapy for RRMM
University of Pennsylvania
NCT04009109 ACTIVE NOT RECRUITING Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Alliance Foundation Trials, LLC.
NCT04068597 RECRUITING Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
NCT03622788 ACTIVE NOT RECRUITING Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT04268199 RECRUITING A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
AHS Cancer Control Alberta
NCT03290950 ACTIVE NOT RECRUITING A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT06518551 RECRUITING Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Omar Nadeem, MD
NCT03346135 ACTIVE NOT RECRUITING Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
City of Hope Medical Center
NCT06049290 RECRUITING A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd
NCT06947083 RECRUITING Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT06920251 RECRUITING Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Seoul National University Hospital
NCT06645678 RECRUITING Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
YOUNGIL KOH
NCT04174196 ACTIVE NOT RECRUITING A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Memorial Sloan Kettering Cancer Center
NCT04649359 ACTIVE NOT RECRUITING MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
NCT07188090 RECRUITING Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University
NCT06517017 RECRUITING Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
University of Utah
NCT07247097 NOT YET RECRUITING ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
Massachusetts General Hospital
NCT04439149 ACTIVE NOT RECRUITING Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
NCT05776979 RECRUITING Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
NCT04439188 ACTIVE NOT RECRUITING Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
NCT02253316 ACTIVE NOT RECRUITING Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Washington University School of Medicine
NCT03315026 ACTIVE NOT RECRUITING Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
NCT05031897 RECRUITING Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05911321 ACTIVE NOT RECRUITING Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
NCT07217184 ACTIVE NOT RECRUITING Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
GlaxoSmithKline
NCT07217119 ACTIVE NOT RECRUITING Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
GlaxoSmithKline
NCT04176718 RECRUITING Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Andrew Yee, MD
NCT07210047 ENROLLING BY INVITATION Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
HuniLife Biotechnology, Inc.
NCT06997081 RECRUITING ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
University of Miami
NCT06052826 RECRUITING Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
City of Hope Medical Center
NCT05632380 RECRUITING ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
NCT04302324 ACTIVE NOT RECRUITING A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
NCT05932680 RECRUITING Limited-duration Teclistamab
Abramson Cancer Center at Penn Medicine
NCT06785415 RECRUITING Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
NCT05145400 RECRUITING Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
NCT04975555 ACTIVE NOT RECRUITING Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
NCT07018050 RECRUITING Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
NCT06572605 RECRUITING External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
City of Hope Medical Center
NCT05572229 RECRUITING Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
University Hospital, Lille
NCT07107204 NOT YET RECRUITING A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
NCT04497961 ACTIVE NOT RECRUITING A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
Memorial Sloan Kettering Cancer Center
NCT03004287 ACTIVE NOT RECRUITING 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
NCT01559935 ACTIVE NOT RECRUITING Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
Weill Medical College of Cornell University
NCT05372354 RECRUITING A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
NCT05208307 RECRUITING Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
NCT07150104 ACTIVE NOT RECRUITING Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
NCT06822972 RECRUITING HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Duke University
NCT07150091 ACTIVE NOT RECRUITING Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
NCT06461988 RECRUITING Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Stanford University
NCT07085728 ACTIVE NOT RECRUITING Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
NCT06616389 RECRUITING Study of ODX (OsteoDex) in Multiple Myeloma
DexTech Medical AB
NCT05900882 RECRUITING SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
The First Affiliated Hospital with Nanjing Medical University
NCT05565807 RECRUITING Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Zhejiang ACEA Pharmaceutical Co. Ltd.
NCT06376526 RECRUITING IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Dickran Kazandjian, MD
NCT03314181 ACTIVE NOT RECRUITING A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT03896737 ACTIVE NOT RECRUITING Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
Stichting European Myeloma Network
NCT04124497 ACTIVE NOT RECRUITING A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients
Fondazione EMN Italy Onlus
NCT04635189 ACTIVE NOT RECRUITING Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
University of Rochester
NCT03314636 ACTIVE NOT RECRUITING Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Oslo University Hospital
NCT03628612 ENROLLING BY INVITATION Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Autolus Limited
NCT07106710 RECRUITING ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT07106671 RECRUITING A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT07106736 RECRUITING MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT07106684 RECRUITING ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT02899052 ACTIVE NOT RECRUITING Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
NCT05841550 RECRUITING The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Oslo University Hospital
NCT05850286 RECRUITING A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
Institute of Hematology & Blood Diseases Hospital, China
NCT06793449 RECRUITING BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT05860036 ACTIVE NOT RECRUITING A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT06880393 RECRUITING BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT06762769 RECRUITING Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
University College, London
NCT07045909 RECRUITING Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
PETHEMA Foundation
NCT07090954 NOT YET RECRUITING A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT04790474 ACTIVE NOT RECRUITING Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
Tel-Aviv Sourasky Medical Center
NCT04052880 ACTIVE NOT RECRUITING Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Larysa Sanchez
NCT07070934 NOT YET RECRUITING CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
Xuzhou Medical University
NCT06171685 RECRUITING MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Multiple Myeloma Research Consortium
NCT07053436 RECRUITING Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Consortium
NCT05123131 ACTIVE NOT RECRUITING Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
Cancer Trials Ireland
NCT02538198 ACTIVE NOT RECRUITING Lenalidomide Maintenance in Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
NCT04775550 ACTIVE NOT RECRUITING DARA RVD For High Risk SMM
Omar Nadeem, MD
NCT00869232 ACTIVE NOT RECRUITING UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
NCT03314974 RECRUITING Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT07032129 RECRUITING Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Essen Biotech
NCT06087653 RECRUITING Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Starton Therapeutics, Inc
NCT05346809 RECRUITING Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Divaya Bhutani
NCT06119685 RECRUITING IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
NCT04649073 ACTIVE NOT RECRUITING Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
Otsuka Pharmaceutical Co., Ltd.
NCT05354557 ACTIVE NOT RECRUITING Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Memorial Sloan Kettering Cancer Center
NCT06971380 RECRUITING Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Polina Stepensky
NCT05294055 RECRUITING Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT05177536 ACTIVE NOT RECRUITING Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
University of Nebraska
NCT06963866 NOT YET RECRUITING Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
Xuzhou Medical University
NCT05908409 RECRUITING A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
IDP Discovery Pharma S.L.
NCT03756896 ACTIVE NOT RECRUITING Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
Emory University
NCT06566547 RECRUITING GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT05469893 RECRUITING Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Irene Ghobrial, MD
NCT06931704 NOT YET RECRUITING Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
Nantes University Hospital
NCT06140966 RECRUITING Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT04891809 ACTIVE NOT RECRUITING Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT04998786 ACTIVE NOT RECRUITING A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
Nantes University Hospital
NCT06911710 RECRUITING The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Tianjin Medical University General Hospital
NCT03376672 ACTIVE NOT RECRUITING Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
Raija Silvennoinen
NCT06880601 NOT YET RECRUITING Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT06484829 RECRUITING Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT05853965 RECRUITING Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
NCT04392037 ACTIVE NOT RECRUITING Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone
Amsterdam UMC, location VUmc
NCT06758375 RECRUITING Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
Hospital Universitario Dr. Jose E. Gonzalez
NCT04717700 ACTIVE NOT RECRUITING Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
Ida Bruun Kristensen
NCT04776330 RECRUITING a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
NCT04271644 RECRUITING BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
NCT04564703 ACTIVE NOT RECRUITING Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
Stichting European Myeloma Network
NCT04965155 ACTIVE NOT RECRUITING A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)
EMN Trial Office S.r.l. Impresa Sociale
NCT06158412 RECRUITING All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
The First Affiliated Hospital of Xiamen University
NCT05597345 RECRUITING Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
NCT06668792 RECRUITING An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Biocad
NCT06799676 NOT YET RECRUITING A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
Fuling Zhou
NCT04782687 ACTIVE NOT RECRUITING Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
NCT06115135 RECRUITING A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
NCT06107738 RECRUITING Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
NCT03715478 ACTIVE NOT RECRUITING Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Canadian Myeloma Research Group
NCT04786028 ACTIVE NOT RECRUITING A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
Canadian Myeloma Research Group
NCT06759181 RECRUITING Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Xuzhou Medical University
NCT06744894 NOT YET RECRUITING SIL as Maintenance Therapy in Multiple Myeloma
Navy General Hospital, Beijing
NCT06083207 RECRUITING A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
NCT02315716 ACTIVE NOT RECRUITING Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
University College, London
NCT02406222 ACTIVE NOT RECRUITING Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
University of Leeds
NCT03989414 ACTIVE NOT RECRUITING A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
NCT06574126 RECRUITING Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
PETHEMA Foundation
NCT06183489 RECRUITING Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Stichting European Myeloma Network
NCT06644443 RECRUITING BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
NCT05299424 RECRUITING A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
NCT04140162 ACTIVE NOT RECRUITING Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
University of Michigan Rogel Cancer Center
NCT04756401 ACTIVE NOT RECRUITING Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
NCT06581640 RECRUITING Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Xiamen University
NCT02542657 ACTIVE NOT RECRUITING Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
Joseph Tuscano
NCT03225417 ACTIVE NOT RECRUITING Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT04879043 RECRUITING Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Heidelberg Pharma AG
NCT06505369 RECRUITING Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
North Estonia Medical Centre
NCT06503107 RECRUITING Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT05880043 RECRUITING GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
GI Cell, Inc.
NCT06430736 RECRUITING PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Insel Gruppe AG, University Hospital Bern
NCT05636787 RECRUITING Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Insel Gruppe AG, University Hospital Bern
NCT03942224 ACTIVE NOT RECRUITING Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Emory University
NCT05422027 RECRUITING Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Xia Zhongjun
NCT06182696 RECRUITING OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
OriCell Therapeutics Co., Ltd.
NCT05493800 ACTIVE NOT RECRUITING Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
MitoImmune Therapeutics
NCT03104842 ACTIVE NOT RECRUITING Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
NCT05982275 NOT YET RECRUITING Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT03188172 ACTIVE NOT RECRUITING MUK Nine b: OPTIMUM Treatment Protocol
University of Leeds
NCT03292263 ACTIVE NOT RECRUITING ASCT With Nivolumab in Patients With Multiple Myeloma
St. Petersburg State Pavlov Medical University
NCT06333509 NOT YET RECRUITING Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
CARsgen Therapeutics Co., Ltd.
NCT06232096 RECRUITING A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Beijing Mabworks Biotech Co., Ltd.
NCT06282978 ACTIVE NOT RECRUITING Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
PETHEMA Foundation
NCT06242249 NOT YET RECRUITING Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Shahid Beheshti University of Medical Sciences
NCT06246162 RECRUITING Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
Affiliated Hospital of Nantong University
NCT05243212 RECRUITING Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Sheba Medical Center
NCT06196255 RECRUITING Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Xuzhou Medical University
NCT03915184 ACTIVE NOT RECRUITING Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
CARsgen Therapeutics Co., Ltd.
NCT03289299 ACTIVE NOT RECRUITING Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
International Myeloma Foundation
NCT06158269 RECRUITING DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
NCT06132711 RECRUITING Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
Xuzhou Medical University
NCT05998928 RECRUITING A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT03673826 ACTIVE NOT RECRUITING Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT04808037 ACTIVE NOT RECRUITING Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
NCT05573802 RECRUITING A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
NCT04558931 RECRUITING Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Karolinska Institutet
NCT05909826 NOT YET RECRUITING Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
Dong-A University Hospital
NCT05308225 ACTIVE NOT RECRUITING Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc.
NCT05521802 RECRUITING A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Shanghai AbelZeta Ltd.
NCT04935684 RECRUITING Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
University Hospital, Clermont-Ferrand
NCT05594797 RECRUITING Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Hrain Biotechnology Co., Ltd.
NCT05581875 NOT YET RECRUITING A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
NCT03852407 RECRUITING Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
University of Liege
NCT02415413 ACTIVE NOT RECRUITING Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
PETHEMA Foundation
NCT05055791 NOT YET RECRUITING A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT03606577 ACTIVE NOT RECRUITING An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
Nantes University Hospital
NCT03815279 ENROLLING BY INVITATION A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
Landspitali University Hospital
NCT04025450 RECRUITING Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
NCT03196414 RECRUITING Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
The First Affiliated Hospital of Soochow University
NCT07600151 NOT YET RECRUITING Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
NCT07589634 NOT YET RECRUITING A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Janssen Research & Development, LLC
NCT07585760 RECRUITING CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment
Institute of Hematology & Blood Diseases Hospital, China
NCT01009840 COMPLETED IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT03757221 TERMINATED Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
University Hospital, Caen
NCT06876142 SUSPENDED Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT02362035 COMPLETED ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Acerta Pharma BV
NCT04731844 COMPLETED Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
NCT04205409 COMPLETED Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
NCT03413800 COMPLETED Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Ciusss de L'Est de l'Île de Montréal
NCT03477539 COMPLETED Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
NCT05064358 COMPLETED Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline
NCT06348147 SUSPENDED Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
UNC Lineberger Comprehensive Cancer Center
NCT04083534 COMPLETED First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
NCT05846737 WITHDRAWN BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
Institute of Hematology & Blood Diseases Hospital, China
NCT01668719 COMPLETED S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
SWOG Cancer Research Network
NCT03622775 TERMINATED Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
M.D. Anderson Cancer Center
NCT05090566 TERMINATED MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
NCT02316106 COMPLETED A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
NCT01816971 COMPLETED Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
NCT02719613 COMPLETED Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
NCT01384513 COMPLETED A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02203643 COMPLETED Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
Mario Boccadoro
NCT01453101 COMPLETED Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Hackensack Meridian Health
NCT02405364 COMPLETED Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction
University Hospital, Toulouse
NCT02626481 COMPLETED Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
University Hospital, Lille
NCT02302495 COMPLETED Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
University Hospital, Lille
NCT01067287 COMPLETED Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Beth Israel Deaconess Medical Center
NCT02681302 TERMINATED Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
Hackensack Meridian Health
NCT01502085 COMPLETED Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens
Hackensack Meridian Health
NCT01242267 COMPLETED Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
Hackensack Meridian Health
NCT01453088 TERMINATED Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
NCT01315132 COMPLETED A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03441958 COMPLETED ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Ciusss de L'Est de l'Île de Montréal
NCT01615029 COMPLETED Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
NCT01572480 COMPLETED Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
National Cancer Institute (NCI)
NCT03361306 COMPLETED LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
NCT05032820 COMPLETED Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
NCT03601078 COMPLETED An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Celgene
NCT01919086 COMPLETED Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT02833610 COMPLETED A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Massachusetts General Hospital
NCT05561751 COMPLETED Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
GPCR Therapeutics, Inc.
NCT04661137 SUSPENDED A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Hackensack Meridian Health
NCT05014412 COMPLETED A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
Pfizer
NCT03374085 TERMINATED A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene
NCT01237054 COMPLETED Imaging in MGUS, SMM and MM
National Cancer Institute (NCI)
NCT01745640 COMPLETED Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
University Hospital, Lille
NCT05590377 TERMINATED A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D LLC
NCT03215030 TERMINATED A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D LLC
NCT03839459 COMPLETED Denosumab for Smoldering Multiple Myeloma
University of Rochester
NCT03159702 COMPLETED Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
NCT02389517 COMPLETED Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
NCT02969837 COMPLETED Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
NCT02441686 COMPLETED Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
NCT05172596 TERMINATED PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Novartis Pharmaceuticals
NCT02619682 COMPLETED Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
NCT07071909 WITHDRAWN Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
NCT05228470 COMPLETED A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
NCT04824794 TERMINATED GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
NCT01665794 COMPLETED Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
NCT03317899 COMPLETED Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03758417 TERMINATED A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Nanjing Legend Biotech Co.
NCT02461888 COMPLETED Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
University of Leeds
NCT02328014 COMPLETED Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
NCT02244125 COMPLETED A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)
Institut Curie
NCT02937571 COMPLETED High Dose Carfilzomib for Newly Diagnosed Myeloma
Memorial Sloan Kettering Cancer Center
NCT06351644 TERMINATED ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Adriana Rossi
NCT03837509 TERMINATED INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Incyte Corporation
NCT01760655 COMPLETED Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01592370 COMPLETED An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
NCT04582539 TERMINATED To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
Incyte Corporation
NCT03590652 TERMINATED Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
NCT03767257 COMPLETED A Study of Colesevelam for Lenalidomide-Associated Diarrhea
Memorial Sloan Kettering Cancer Center
NCT02412228 COMPLETED Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
John L. Reagan
NCT03731832 COMPLETED Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
GWT-TUD GmbH
NCT02356159 COMPLETED Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT02858999 COMPLETED Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70
Centre Hospitalier Universitaire, Amiens
NCT04855136 TERMINATED Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Celgene
NCT01745588 COMPLETED Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT01415882 COMPLETED Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
NCT04191616 COMPLETED Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Amgen
NCT03525678 COMPLETED A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
GlaxoSmithKline
NCT03376477 TERMINATED Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05288062 TERMINATED Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
NCT02916771 COMPLETED Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
NCT07102706 COMPLETED Phase I Trial of GR1803 Injection in Patients With RRMM
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT03548207 COMPLETED A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
NCT03862131 TERMINATED PROactive Evaluation of Function to Avoid CardioToxicity
Washington University School of Medicine
NCT01864018 COMPLETED Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
NCT06055075 COMPLETED A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
NCT03333486 TERMINATED Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT02722668 COMPLETED UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT02765854 COMPLETED Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
NCT03713294 COMPLETED Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Mayo Clinic
NCT05839626 TERMINATED A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
NCT01946477 COMPLETED Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
Celgene
NCT03012880 COMPLETED Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
NCT03246906 TERMINATED Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT01350258 TERMINATED Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04735575 TERMINATED A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd.
NCT03490344 COMPLETED Short Course Daratumumab in Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT03361748 COMPLETED Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene
NCT01125449 WITHDRAWN Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
NCT04176380 COMPLETED RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC
NCT01729091 COMPLETED Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
M.D. Anderson Cancer Center
NCT01532635 TERMINATED A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04892446 TERMINATED Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
NCT03417284 COMPLETED Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT02224729 COMPLETED Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03412565 COMPLETED A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
NCT05347485 COMPLETED A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Janssen Scientific Affairs, LLC
NCT03860038 COMPLETED TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ Biopharma Co., Ltd.
NCT02566304 COMPLETED Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04896658 TERMINATED Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
NCT06682637 WITHDRAWN Melflufen for Elderly Patients With Relapsed Myeloma
Fondazione EMN Italy Onlus
NCT03700450 COMPLETED Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
NCT03871829 TERMINATED Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Janssen Research & Development, LLC
NCT03442673 COMPLETED Chemotherapy and G-CSF for Mobilization
Insel Gruppe AG, University Hospital Bern
NCT04939844 COMPLETED REST - Replacing Steroids in the Transplant Ineligble
Oslo University Hospital
NCT02649790 COMPLETED Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
NCT02506959 COMPLETED Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
NCT03544281 COMPLETED To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
NCT03457142 TERMINATED Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Roswell Park Cancer Institute
NCT01997840 TERMINATED ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Celgene
NCT06352866 WITHDRAWN Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Jack Khouri, MD
NCT06655818 TERMINATED Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
GlaxoSmithKline
NCT04700176 TERMINATED A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
NCT03683277 TERMINATED IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic
Intergroupe Francophone du Myelome
NCT04150965 TERMINATED Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Multiple Myeloma Research Consortium
NCT03732703 COMPLETED Myeloma-Developing Regimens Using Genomics (MyDRUG)
Multiple Myeloma Research Consortium
NCT03792763 COMPLETED Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT03398200 COMPLETED Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma
Omar Aljitawi
NCT02874742 COMPLETED Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Janssen Research & Development, LLC
NCT03187223 COMPLETED Bendamustine and Melphalan in Myeloma
Insel Gruppe AG, University Hospital Bern
NCT05117008 TERMINATED Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
NCT01718743 COMPLETED Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
NCT05427812 TERMINATED Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
NCT05191472 TERMINATED Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Alfred Chung, MD
NCT03773107 COMPLETED LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Wake Forest University Health Sciences
NCT03997968 COMPLETED A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
NCT01903811 COMPLETED S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
NCT00965224 COMPLETED Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma
Zwi Berneman
NCT01919619 COMPLETED Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT04436029 COMPLETED Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Cartesian Therapeutics
NCT06050512 WITHDRAWN Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Kathleen Dorritie
NCT04099901 COMPLETED Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial
Radboud University Medical Center
NCT03233776 COMPLETED Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT
Radboud University Medical Center
NCT01857115 COMPLETED Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)
European Myeloma Network B.V.
NCT01755975 COMPLETED Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Memorial Sloan Kettering Cancer Center
NCT04816526 TERMINATED Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Cartesian Therapeutics
NCT00747123 COMPLETED A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Celgene
NCT04776018 TERMINATED A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Takeda
NCT02375555 COMPLETED Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Dana-Farber Cancer Institute
NCT02633059 COMPLETED Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
NCT02002598 TERMINATED Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Suzanne Lentzsch, MD
NCT01827137 COMPLETED WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
NCT03000634 WITHDRAWN 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
University of Arkansas
NCT03267888 COMPLETED Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Emory University
NCT04847050 COMPLETED A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Cancer Institute (NCI)
NCT01183949 COMPLETED Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
NCT05050305 WITHDRAWN Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
NCT02654990 COMPLETED Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
pharmaand GmbH
NCT05820763 WITHDRAWN Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
NCT05204160 WITHDRAWN Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Emory University
NCT02863991 TERMINATED Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
NCT03439293 COMPLETED A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda
NCT04111107 TERMINATED Precision Medicine for Patients With Identified Actionable Mutations
Wake Forest University Health Sciences
NCT04352205 TERMINATED Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
NCT05000450 TERMINATED Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics
NCT04379817 COMPLETED Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Jules Bordet Institute
NCT01670994 TERMINATED QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
NCT03194867 COMPLETED Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Sanofi
NCT01283997 COMPLETED Prevention of Treatment Induced Neuropathy in Multiple Myeloma
M.D. Anderson Cancer Center
NCT03430011 COMPLETED Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
NCT03184194 COMPLETED Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide
Amsterdam UMC, location VUmc
NCT02586038 COMPLETED STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
Mario Boccadoro
NCT02728102 COMPLETED Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
NCT06400264 WITHDRAWN Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
NCT04407442 TERMINATED Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
University of California, San Francisco
NCT01063907 COMPLETED A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
NCT02661022 TERMINATED SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Stemline Therapeutics, Inc.
NCT03848845 COMPLETED Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
NCT04028115 COMPLETED Bone Healing During Ninlaro Exposure
Thomas Lund
NCT02812706 COMPLETED Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
Sanofi
NCT02891811 COMPLETED Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT03450057 COMPLETED Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment
Hellenic Society of Hematology
NCT03288493 TERMINATED P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Poseida Therapeutics, Inc.
NCT02119468 COMPLETED Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
NCT02700841 TERMINATED Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
University of Nebraska
NCT06160609 TERMINATED Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
GlaxoSmithKline
NCT02056756 COMPLETED Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
Stichting European Myeloma Network
NCT04478123 COMPLETED Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Memorial Sloan Kettering Cancer Center
NCT04465760 TERMINATED Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
OHSU Knight Cancer Institute
NCT01190787 COMPLETED Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
European Myeloma Network B.V.
NCT06212596 COMPLETED Selinexor, Cyclophosphamide and Prednisone in Myeloma
University of Leeds
NCT04505813 SUSPENDED Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
NexImmune Inc.
NCT03506360 COMPLETED Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
NCT03128359 COMPLETED High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT05028374 COMPLETED COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
NCT04682405 COMPLETED Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Washington University School of Medicine
NCT01913730 COMPLETED Maintenance Therapy With Subcutaneous Bortezomib
European Myeloma Network B.V.
NCT02843074 COMPLETED Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
SCRI Development Innovations, LLC
NCT03224507 COMPLETED Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
University of Alabama at Birmingham
NCT02834364 COMPLETED BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
University of Heidelberg Medical Center
NCT04864522 WITHDRAWN Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma
University of Virginia
NCT05647512 WITHDRAWN Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
NCT05321862 WITHDRAWN Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.
Nantes University Hospital
NCT02639559 COMPLETED Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT02188368 TERMINATED Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Oncotherapeutics
NCT02294357 TERMINATED Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
NCT02206425 COMPLETED Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
NCT02547662 COMPLETED Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
NCT00777998 COMPLETED Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
NCT04843579 TERMINATED Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
Weill Medical College of Cornell University
NCT03733691 TERMINATED Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Oncotherapeutics
NCT02308280 COMPLETED Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
Maisonneuve-Rosemont Hospital
NCT02509052 COMPLETED Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
NCT01177683 TERMINATED Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Sherif Farag, MB, BS
NCT02685826 COMPLETED A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
Celgene
NCT04205240 TERMINATED Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Srinivas Devarakonda
NCT03701321 WITHDRAWN Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT03155100 COMPLETED Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines
Raija Silvennoinen
NCT03202628 COMPLETED Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT02661035 COMPLETED Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01346787 COMPLETED Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
European Myeloma Network B.V.
NCT03201250 TERMINATED Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
University of Nebraska
NCT04258683 WITHDRAWN A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
NCT02597062 COMPLETED High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
Canadian Cancer Trials Group
NCT02906332 TERMINATED Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Hackensack Meridian Health
NCT04445701 COMPLETED Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Arch Oncology
NCT04119336 TERMINATED Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Andrew Yee, MD
NCT01145989 COMPLETED A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
NCIC Clinical Trials Group
NCT03215524 COMPLETED A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide
Canadian Myeloma Research Group
NCT01936532 COMPLETED Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Nantes University Hospital
NCT03959358 COMPLETED A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
University Health Network, Toronto
NCT02204241 COMPLETED Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
European Myeloma Network B.V.
NCT02185820 COMPLETED Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
European Myeloma Network B.V.
NCT01160107 COMPLETED Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients
Fondazione EMN Italy Onlus
NCT01572662 COMPLETED Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
NCT01166113 COMPLETED Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
Fondazione EMN Italy Onlus
NCT01348919 COMPLETED Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
NCT03782064 TERMINATED Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Beth Israel Deaconess Medical Center
NCT02794246 TERMINATED CART-19 Post-ASCT for Multiple Myeloma
University of Pennsylvania
NCT03944057 COMPLETED A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
Antengene Corporation
NCT02903381 COMPLETED A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Dana-Farber Cancer Institute
NCT02279394 COMPLETED E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
NCT01264315 COMPLETED Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
Fondazione EMN Italy Onlus
NCT02416206 COMPLETED High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Northside Hospital, Inc.
NCT02751255 COMPLETED Daratumumab in Combination With ATRA
Amsterdam UMC, location VUmc
NCT02581007 COMPLETED Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT05393999 WITHDRAWN SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
Imperial College Healthcare NHS Trust
NCT01794520 COMPLETED Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT01040026 COMPLETED Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
University Hospital, Basel, Switzerland
NCT03238599 COMPLETED Pedometer Activity Monitoring After ASCT
Insel Gruppe AG, University Hospital Bern
NCT03411031 TERMINATED Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
H. Lee Moffitt Cancer Center and Research Institute
NCT04635735 TERMINATED Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT03639610 TERMINATED PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
Oncopeptides AB
NCT03312530 COMPLETED A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
Hoffmann-La Roche
NCT05338047 COMPLETED Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant
Hospital Universitario Dr. Jose E. Gonzalez
NCT03439280 COMPLETED A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Millennium Pharmaceuticals, Inc.
NCT02807454 TERMINATED A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
Celgene
NCT05007652 COMPLETED A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
Kyowa Kirin Co., Ltd.
NCT05493618 WITHDRAWN Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Hackensack Meridian Health
NCT05408026 WITHDRAWN Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
NCT02336815 COMPLETED Selinexor Treatment of Refractory Myeloma
Karyopharm Therapeutics Inc
NCT02389543 WITHDRAWN Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Karyopharm Therapeutics Inc
NCT02628704 WITHDRAWN Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Karyopharm Therapeutics Inc
NCT01028716 TERMINATED Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT02593123 COMPLETED Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT01838369 TERMINATED A Phase II Study of BI-505 in Smoldering Multiple Myeloma
BioInvent International AB
NCT02393248 TERMINATED Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
NCT02186834 COMPLETED Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT02440464 COMPLETED Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
National Heart, Lung, and Blood Institute (NHLBI)
NCT03170882 COMPLETED A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
Millennium Pharmaceuticals, Inc.
NCT03481556 TERMINATED Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Oncopeptides AB
NCT01177397 COMPLETED Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT04223661 WITHDRAWN Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Attaya Suvannasankha
NCT01947140 COMPLETED Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT02963493 COMPLETED A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Oncopeptides AB
NCT01881789 TERMINATED Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
Amgen
NCT01416428 TERMINATED Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Amgen
NCT02780609 COMPLETED Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT02556931 COMPLETED Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02654132 COMPLETED An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Bristol-Myers Squibb
NCT02722941 COMPLETED Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
H. Lee Moffitt Cancer Center and Research Institute
NCT01677858 COMPLETED A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
Amgen
NCT01702831 COMPLETED Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance
University Health Network, Toronto
NCT04552743 COMPLETED MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
Surbhi Sidana, MD
NCT01119066 COMPLETED HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
NCT01464034 TERMINATED A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Criterium, Inc.
NCT02384083 COMPLETED Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
PETHEMA Foundation
NCT01555281 TERMINATED Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
Swiss Cancer Institute
NCT04802031 WITHDRAWN Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
Thomas Martin, MD
NCT04467281 WITHDRAWN A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
Memorial Sloan Kettering Cancer Center
NCT02272803 COMPLETED Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
Bristol-Myers Squibb
NCT03841565 WITHDRAWN Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Academic and Community Cancer Research United
NCT02977494 COMPLETED Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
Universitätsklinikum Hamburg-Eppendorf
NCT01849783 COMPLETED Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Margarida Magalhaes-Silverman
NCT03256045 TERMINATED Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
University of Washington
NCT01463670 COMPLETED Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
Memorial Sloan Kettering Cancer Center
NCT01658241 COMPLETED Panobinostat Biological Correlates Study
Peter MacCallum Cancer Centre, Australia
NCT03303950 TERMINATED Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
University of Utah
NCT05170789 WITHDRAWN Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
Tulane University School of Medicine
NCT04361851 WITHDRAWN Study of Dara-Pembro for Multiple Myeloma Patients
Wake Forest University Health Sciences
NCT04230031 WITHDRAWN Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Wake Forest University Health Sciences
NCT03964688 COMPLETED Effect of Vitamin C in Autologous Stem Cell Transplantations
Maastricht University Medical Center
NCT03850522 TERMINATED PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
Lene Meldgaard Knudsen
NCT03104270 TERMINATED Combination Study for High Risk Multiple Myeloma Patients
Oncotherapeutics
NCT01989598 COMPLETED Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT03697629 COMPLETED A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Canadian Myeloma Research Group
NCT00792506 TERMINATED Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Italfarmaco
NCT01496118 COMPLETED Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
SCRI Development Innovations, LLC
NCT03875495 TERMINATED A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Genenta Science
NCT02424851 COMPLETED Optimising Renal Outcome in Myeloma Renal Failure
Oxford University Hospitals NHS Trust
NCT04065789 COMPLETED Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
Tel-Aviv Sourasky Medical Center
NCT04150692 WITHDRAWN Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
Washington University School of Medicine
NCT04097301 TERMINATED Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
AGC Biologics S.p.A.
NCT01962792 COMPLETED Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
Pharmacyclics LLC.
NCT02086552 COMPLETED Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
NCT01131169 COMPLETED Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Memorial Sloan Kettering Cancer Center
NCT01793051 COMPLETED Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
M.D. Anderson Cancer Center
NCT01421186 COMPLETED A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
MorphoSys AG
NCT01054144 COMPLETED Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT02951819 COMPLETED A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Janssen Scientific Affairs, LLC
NCT01045382 TERMINATED MSC and HSC Coinfusion in Mismatched Minitransplants
University of Liege
NCT02169791 COMPLETED Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
NCT02045017 COMPLETED Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
NCT03136653 COMPLETED A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
Molecular Partners AG
NCT04584307 WITHDRAWN Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
Natalie Callendar
NCT00792142 COMPLETED Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
NCT01101594 TERMINATED A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Gilead Sciences
NCT01720875 COMPLETED Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)
University of Leeds
NCT03634800 TERMINATED Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
Weill Medical College of Cornell University
NCT02265731 COMPLETED Study Evaluating Venetoclax in Subjects With Hematological Malignancies
AbbVie
NCT01946152 TERMINATED Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT03665155 COMPLETED First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
Memorial Sloan Kettering Cancer Center
NCT02612779 COMPLETED A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Bristol-Myers Squibb
NCT03567616 TERMINATED A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT04439240 COMPLETED Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
National Cancer Institute (NCI)
NCT02128230 TERMINATED UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
NCT03687125 TERMINATED Tinostamustine Conditioning and Autologous Stem Cell
Mundipharma-EDO GmbH
NCT02703779 COMPLETED Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Siddhartha Ganguly
NCT02757326 TERMINATED ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
RedHill Biopharma Limited
NCT02499081 COMPLETED UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
University of Arkansas
NCT03520985 TERMINATED Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
Swiss Cancer Institute
NCT02420223 COMPLETED Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients
Medical College of Wisconsin
NCT03910439 TERMINATED Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT01018979 COMPLETED Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
GPCR Therapeutics, Inc.
NCT01177735 COMPLETED Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
University of Arkansas
NCT02104427 COMPLETED PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
GPCR Therapeutics, Inc.
NCT01458288 COMPLETED A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
GPCR Therapeutics, Inc.
NCT01045460 COMPLETED Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04439214 COMPLETED Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
National Cancer Institute (NCI)
NCT03340883 TERMINATED Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
Chinook Therapeutics, Inc.
NCT00773838 COMPLETED Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
Merck Sharp & Dohme LLC
NCT03262389 COMPLETED Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Michael C Roarke, MD
NCT01402284 COMPLETED Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
National Cancer Institute (NCI)
NCT01753453 COMPLETED An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
Sanofi
NCT02078102 COMPLETED A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Sherif S. Farag
NCT01380106 COMPLETED Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Boston VA Research Institute, Inc.
NCT02917941 COMPLETED A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
NCT03512353 TERMINATED A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Amgen
NCT01930162 COMPLETED Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
Novartis Pharmaceuticals
NCT01058434 COMPLETED Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
Novartis Pharmaceuticals
NCT00708292 COMPLETED A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Novartis Pharmaceuticals
NCT01302886 COMPLETED Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
Novartis Pharmaceuticals
NCT01337752 COMPLETED Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Novartis Pharmaceuticals
NCT02943473 TERMINATED Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Icahn School of Medicine at Mount Sinai
NCT01121120 TERMINATED Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Tarix Pharmaceuticals
NCT01045681 COMPLETED Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
Intergroupe Francophone du Myelome
NCT01426828 COMPLETED Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
University of Pennsylvania
NCT03117361 TERMINATED Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
PharmaMar
NCT01155583 COMPLETED Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
NCT02897830 TERMINATED Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
University Hospital, Toulouse
NCT03033316 TERMINATED A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma
Enceladus Pharmaceuticals BV
NCT00966693 COMPLETED Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT03287804 TERMINATED APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
Autolus Limited
NCT01897714 TERMINATED Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Oncopeptides AB
NCT02477215 COMPLETED Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Parameswaran Hari
NCT02217163 COMPLETED Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma
Singapore General Hospital
NCT02092922 COMPLETED A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Pfizer
NCT02237261 COMPLETED Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
University Hospital Heidelberg
NCT02192775 COMPLETED UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
University of Arkansas
NCT00821249 COMPLETED A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
NCT02991898 TERMINATED Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT02952573 TERMINATED Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
University Health Network, Toronto
NCT01989325 COMPLETED A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
Pfizer
NCT00718419 COMPLETED A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Eli Lilly and Company
NCT01842308 COMPLETED Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
NCT00570180 COMPLETED Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
University Health Network, Toronto
NCT01605032 COMPLETED Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Albert Einstein College of Medicine
NCT01885897 COMPLETED IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Masonic Cancer Center, University of Minnesota
NCT00941720 COMPLETED Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Case Comprehensive Cancer Center
NCT04439305 WITHDRAWN Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
NCT02219178 COMPLETED Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Cancer Trials Ireland
NCT01832727 TERMINATED Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Amgen
NCT03003728 WITHDRAWN 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
University of Arkansas
NCT01858558 COMPLETED Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00903968 COMPLETED Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute
NCT03492138 TERMINATED Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Ajai Chari
NCT02003625 COMPLETED Meloxicam vs Placebo for Mobilization
Massachusetts General Hospital
NCT01237951 COMPLETED High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
M.D. Anderson Cancer Center
NCT02636010 COMPLETED Pembrolizumab (MK-3475) in MM Patients With Residual Disease
PETHEMA Foundation
NCT01660633 COMPLETED Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
Acrotech Biopharma Inc.
NCT01212952 COMPLETED Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT01245673 COMPLETED Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
University of Pennsylvania
NCT04024384 WITHDRAWN Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
Assistance Publique - Hôpitaux de Paris
NCT02902965 COMPLETED Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Pharmacyclics Switzerland GmbH
NCT02756728 TERMINATED A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
BioInvent International AB
NCT00918333 COMPLETED Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT01478581 COMPLETED Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Pharmacyclics LLC.
NCT02168101 COMPLETED Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
SCRI Development Innovations, LLC
NCT02928029 TERMINATED Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Bayer
NCT01438177 TERMINATED Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
NCT03328936 WITHDRAWN Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Ohio State University Comprehensive Cancer Center
NCT03242460 COMPLETED The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
Kosin University Gospel Hospital
NCT01049945 COMPLETED Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
NCT00789776 COMPLETED Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT03196947 TERMINATED Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP
Allarity Therapeutics
NCT04243109 TERMINATED Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
Maimónides Biomedical Research Institute of Córdoba
NCT01484275 COMPLETED A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
NCT00861965 TERMINATED Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Mirror Biologics, Inc.
NCT00558675 COMPLETED A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Mirror Biologics, Inc.
NCT00793572 COMPLETED Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
NCT00772915 COMPLETED Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
NCT00651937 COMPLETED Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
M.D. Anderson Cancer Center
NCT03608501 WITHDRAWN A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
Takeda
NCT01527045 COMPLETED Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT00723099 COMPLETED Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00925782 COMPLETED PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Acrotech Biopharma Inc.
NCT01660997 WITHDRAWN MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
NCT01326702 COMPLETED Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT01571726 WITHDRAWN Imaging Studies and the Development of Multiple Myeloma
National Cancer Institute (NCI)
NCT02410694 COMPLETED Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT01647165 WITHDRAWN Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Cancer Institute (NCI)
NCT02057640 COMPLETED MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Jason Valent
NCT02682953 WITHDRAWN Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
University of Maryland, Baltimore
NCT01239368 TERMINATED Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
National Cancer Institute (NCI)
NCT01251575 COMPLETED Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01352286 COMPLETED Redirected Auto T Cells for Advanced Myeloma
GlaxoSmithKline
NCT02112045 TERMINATED A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
Washington University School of Medicine
NCT00765102 TERMINATED Trial of Romidepsin and Bortezomib for Multiple Myeloma
Celgene
NCT02548962 TERMINATED Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Pharmacyclics LLC.
NCT01248455 TERMINATED A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
National Cancer Institute (NCI)
NCT02290431 COMPLETED Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Novartis Pharmaceuticals
NCT03952832 WITHDRAWN Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
NCT02348528 COMPLETED Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
Celgene
NCT02289222 TERMINATED 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Ashraf Badros
NCT01783522 TERMINATED Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
Beth Faiman
NCT01142232 COMPLETED Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Attaya Suvannasankha
NCT01602224 COMPLETED A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
Eli Lilly and Company
NCT01529827 COMPLETED Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT00948922 COMPLETED Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT01955434 COMPLETED SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT02944565 COMPLETED Daratumumab in Treating Patients With Multiple Myeloma
Ohio State University Comprehensive Cancer Center
NCT00997386 COMPLETED Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
University of Arizona
NCT03785184 WITHDRAWN A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
AbbVie
NCT01447914 COMPLETED Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT01001442 COMPLETED Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Biotest Pharmaceuticals Corporation
NCT02880228 COMPLETED Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
Mayo Clinic
NCT01638936 COMPLETED BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
Biotest Pharmaceuticals Corporation
NCT03393273 WITHDRAWN Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
Assistance Publique - Hôpitaux de Paris
NCT02046070 COMPLETED Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc.
NCT02159365 COMPLETED Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Bristol-Myers Squibb
NCT01875237 TERMINATED Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
NCT02188537 COMPLETED Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Swiss Cancer Institute
NCT01159067 TERMINATED Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
NCT02176213 COMPLETED Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Ajai Chari
NCT01008462 COMPLETED Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Fred Hutchinson Cancer Center
NCT01159574 COMPLETED Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Weill Medical College of Cornell University
NCT00916058 COMPLETED Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Weill Medical College of Cornell University
NCT03333746 TERMINATED Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Yvonne Efebera
NCT02907073 TERMINATED Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
Mayo Clinic
NCT01517724 COMPLETED Bortezomib Consolidation Trial
University College, London
NCT01246063 COMPLETED Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Washington University School of Medicine
NCT01116232 TERMINATED Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
NCT03856112 WITHDRAWN Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT03221634 WITHDRAWN Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Merck Sharp & Dohme LLC
NCT01383928 COMPLETED Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
NCT00807599 COMPLETED Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
Memorial Sloan Kettering Cancer Center
NCT00648739 TERMINATED Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Alexion Pharmaceuticals, Inc.
NCT01481194 COMPLETED ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma
Vejle Hospital
NCT01790737 COMPLETED First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02
Kuopio University Hospital
NCT00920556 TERMINATED A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Sirtris, a GSK Company
NCT00943319 COMPLETED Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
University of Chicago
NCT02275403 COMPLETED Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma
The Christie NHS Foundation Trust
NCT02566265 COMPLETED Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
Yale University
NCT03168100 WITHDRAWN 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
University of Arkansas
NCT01408563 COMPLETED Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT01349569 COMPLETED Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03218163 TERMINATED MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01892293 TERMINATED CT Antigen TCR-Engineered T Cells for Myeloma
Adaptimmune
NCT01303965 TERMINATED Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
Sherif S. Farag
NCT01479582 WITHDRAWN Providing Access to Cord Blood Units for Transplants
National Cancer Institute (NCI)
NCT01374217 TERMINATED Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00709592 COMPLETED Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Virginia Commonwealth University
NCT01698801 COMPLETED A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
Celgene
NCT01782963 COMPLETED Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Massachusetts General Hospital
NCT00790842 TERMINATED Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
PrECOG, LLC.
NCT00896454 COMPLETED Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
NCT03000452 COMPLETED A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene
NCT01676961 TERMINATED Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
NYU Langone Health
NCT02075021 TERMINATED Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
NYU Langone Health
NCT02669615 COMPLETED Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Medical College of Wisconsin
NCT01355705 COMPLETED Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Michaela Liedtke
NCT01706666 COMPLETED Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
Mayo Clinic
NCT01672736 TERMINATED A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
University Health Network, Toronto
NCT01273766 COMPLETED Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
NCT01272466 COMPLETED Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma
Herlev Hospital
NCT01794039 COMPLETED Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
Mayo Clinic
NCT02986451 WITHDRAWN Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
Sun Yat-sen University
NCT03227432 WITHDRAWN An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Dana-Farber Cancer Institute
NCT01852799 COMPLETED A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
Shanghai Changzheng Hospital
NCT01690143 COMPLETED Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
University of Alabama at Birmingham
NCT02206503 COMPLETED Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
Fondazione EMN Italy Onlus
NCT02331368 COMPLETED Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
University of Michigan Rogel Cancer Center
NCT02720510 TERMINATED A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Novartis Pharmaceuticals
NCT01484626 TERMINATED Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
Loyola University
NCT01526694 COMPLETED Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Azienda Ospedaliera di Bolzano
NCT01985126 COMPLETED An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
Janssen Research & Development, LLC
NCT00664378 TERMINATED Efficacy Study of CYT997 in Multiple Myeloma
Gilead Sciences
NCT01979276 TERMINATED Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Weill Medical College of Cornell University
NCT01174082 TERMINATED Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
M.D. Anderson Cancer Center
NCT01478048 COMPLETED Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
NCT01215344 COMPLETED First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Vanderbilt-Ingram Cancer Center
NCT00884312 COMPLETED A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
Amgen
NCT02985333 WITHDRAWN Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
NCT02372240 TERMINATED A Study of VLX1570 and Dexamethasone in Myeloma Patients
Vivolux AB
NCT00984165 TERMINATED Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)
NCT00574288 COMPLETED Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Janssen Research & Development, LLC
NCT01651039 COMPLETED Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
Ajai Chari
NCT02791373 COMPLETED Vinorelbine and Gemcitabine in Myeloma
Insel Gruppe AG, University Hospital Bern
NCT01217957 COMPLETED A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
NCT01547806 COMPLETED Collection of Transplant Stem Cells for Plasma Cell Myeloma
National Cancer Institute (NCI)
NCT01365559 COMPLETED Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Oncotherapeutics
NCT00639002 COMPLETED A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Incyte Corporation
NCT01315873 TERMINATED Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
NCT01675141 TERMINATED Lenalidomide Maintenance Therapy for Multiple Myeloma
National Cancer Institute (NCI)
NCT01441973 COMPLETED Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bristol-Myers Squibb
NCT01335685 COMPLETED Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
NCT01332617 WITHDRAWN Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
University of Louisville
NCT01270932 COMPLETED Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
University Health Network, Toronto
NCT00963872 TERMINATED Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Masonic Cancer Center, University of Minnesota
NCT01083602 COMPLETED Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Novartis Pharmaceuticals
NCT03100877 WITHDRAWN Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
City of Hope Medical Center
NCT01057225 COMPLETED Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Mayo Clinic
NCT01343368 TERMINATED Preservation of Ovarian Function After Hematopoietic Cell Transplant
Masonic Cancer Center, University of Minnesota
NCT01518465 TERMINATED Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
University of Southern California
NCT01255514 COMPLETED Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Yonsei University
NCT01969565 TERMINATED Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma
Emory University
NCT01524978 COMPLETED A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Hoffmann-La Roche
NCT02046915 COMPLETED Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide
University Hospital Tuebingen
NCT00899847 COMPLETED Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Stanford University
NCT01646762 TERMINATED Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT01251172 WITHDRAWN RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
NCT01593410 COMPLETED Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
Celgene
NCT00849251 TERMINATED Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
University of Washington
NCT00857324 TERMINATED Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients
Tiziana Marangon
NCT01720043 TERMINATED Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
University of Utah
NCT00670631 COMPLETED Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment
Guido Tricot
NCT01866293 COMPLETED Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Memorial Sloan Kettering Cancer Center
NCT03191981 WITHDRAWN Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
University of Leeds
NCT01339572 COMPLETED Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
University of Florida
NCT00837200 TERMINATED Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Milton S. Hershey Medical Center
NCT00843310 TERMINATED Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
NYU Langone Health
NCT02098109 COMPLETED Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
NCT01460420 COMPLETED Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation
European Myeloma Network B.V.
NCT00691015 COMPLETED Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
NCT01775553 COMPLETED Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Ajai Chari
NCT01548573 TERMINATED Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
NCT01965834 TERMINATED Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
University of Miami
NCT02619812 TERMINATED Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
Mayo Clinic
NCT01158118 COMPLETED Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
NCT00724568 COMPLETED Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
University of Michigan Rogel Cancer Center
NCT01729338 TERMINATED Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Duke University
NCT00448201 COMPLETED Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
NCT01110135 COMPLETED Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
NCT01432600 COMPLETED Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
NCT00795769 COMPLETED Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01313897 COMPLETED UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
University of Arkansas
NCT01427881 COMPLETED Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT00619684 COMPLETED Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01206205 COMPLETED Frontline Therapy in de Novo Multiple Myeloma Patients Under 65
University Hospital, Toulouse
NCT02260414 COMPLETED Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Centre Hospitalier Universitaire de Saint Etienne
NCT00839956 COMPLETED Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01056276 COMPLETED Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
SCRI Development Innovations, LLC
NCT00721734 COMPLETED Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Amgen
NCT02072863 COMPLETED A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Amgen
NCT02802163 WITHDRAWN Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
H. Lee Moffitt Cancer Center and Research Institute
NCT01884688 COMPLETED UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
University of Arkansas
NCT01632150 COMPLETED Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Bristol-Myers Squibb
NCT01351623 COMPLETED Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT01323751 COMPLETED Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Celgene
NCT01534143 TERMINATED High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
NCT01118013 TERMINATED Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
NCT01207765 TERMINATED Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Tufts Medical Center
NCT01484314 TERMINATED Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
Dana-Farber Cancer Institute
NCT01019174 COMPLETED Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
NCT00679367 COMPLETED Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
NCT02254551 TERMINATED Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
SCRI Development Innovations, LLC
NCT02402725 WITHDRAWN A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
Boston Medical Center
NCT00635024 TERMINATED Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
NCT00790647 COMPLETED Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
NCT01029054 COMPLETED Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
University of Michigan Rogel Cancer Center
NCT02578121 WITHDRAWN UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
University of Arkansas
NCT01237249 COMPLETED Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
PETHEMA Foundation
NCT01695330 TERMINATED Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
Oncotherapeutics
NCT01812720 WITHDRAWN Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Mayo Clinic
NCT02756663 WITHDRAWN Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Novartis Pharmaceuticals
NCT02020941 TERMINATED Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
Attaya Suvannasankha
NCT02011113 COMPLETED Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
NCT00891618 COMPLETED Acupuncture for Chemo-Induced Peripheral Neuropathy
M.D. Anderson Cancer Center
NCT01699581 TERMINATED Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
Greg Monohan
NCT02471820 COMPLETED Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients
Meletios A. Dimopoulos
NCT00779922 COMPLETED Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Poitiers University Hospital
NCT02605356 WITHDRAWN Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Bayer
NCT02573935 TERMINATED Clarithromycin in Multiple Myeloma Induction Therapy
Henrik Gregersen
NCT00800839 COMPLETED Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
NCT02230917 WITHDRAWN A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Rebecca Silbermann
NCT01701076 COMPLETED Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Cantonal Hospital of St. Gallen
NCT01319422 COMPLETED Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Yale University
NCT01096810 TERMINATED Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma
Jagannath, Sundar, M.D.
NCT01652014 WITHDRAWN Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
University of Medicine and Dentistry of New Jersey
NCT00983346 TERMINATED Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
NCT01079936 COMPLETED Lenalidomide and High-Dose Melphalan
M.D. Anderson Cancer Center
NCT01658904 TERMINATED Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
National Cancer Institute (NCI)
NCT01286077 COMPLETED Velcade Consolidation Bone Study
Janssen-Cilag International NV
NCT01034553 COMPLETED Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT01376401 COMPLETED Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
PETHEMA Foundation
NCT01242930 COMPLETED Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Geron Corporation
NCT01501370 WITHDRAWN Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy
Tiziana Marangon
NCT00833833 COMPLETED MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
NCT01279694 COMPLETED Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
Nantes University Hospital
NCT01023880 TERMINATED Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Cephalon
NCT02140840 WITHDRAWN UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib
University of Arkansas
NCT01394354 COMPLETED Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
University Hospital Freiburg
NCT00615589 TERMINATED Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
University of Michigan Rogel Cancer Center
NCT01450215 COMPLETED Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma
Karolinska University Hospital
NCT00999830 COMPLETED Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
Innate Pharma
NCT01518153 TERMINATED Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
NCT00618969 COMPLETED Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
University of Arizona
NCT00975975 COMPLETED Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Indiana University
NCT01413568 COMPLETED Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Polyphor Ltd.
NCT01352338 COMPLETED Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
UMC Utrecht
NCT01094548 COMPLETED Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Merck KGaA, Darmstadt, Germany
NCT01329289 WITHDRAWN SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
NCT01624701 TERMINATED Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells
Singapore General Hospital
NCT01053949 COMPLETED IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
University Hospital, Lille
NCT01521533 COMPLETED NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
TME Pharma AG
NCT01084837 COMPLETED Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure
PETHEMA Foundation
NCT01085214 COMPLETED AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
NCT02221479 COMPLETED Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Genzyme, a Sanofi Company
NCT01531998 COMPLETED Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
M.D. Anderson Cancer Center
NCT02467010 COMPLETED Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance
University Medical Center Groningen
NCT00998049 COMPLETED Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Mayo Clinic
NCT00778752 COMPLETED Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
NCT01160484 COMPLETED Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
NCT02082405 WITHDRAWN Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma
Case Comprehensive Cancer Center
NCT00706953 WITHDRAWN A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT01062230 TERMINATED Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
University of Arkansas
NCT00942422 TERMINATED Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
NCT00555906 COMPLETED An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
Pfizer
NCT02353468 TERMINATED Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
University of Colorado, Denver
NCT02353572 TERMINATED Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
University of Colorado, Denver
NCT01055301 WITHDRAWN S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
SWOG Cancer Research Network
NCT00809276 COMPLETED Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01302366 TERMINATED A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
NYU Langone Health
NCT01849848 COMPLETED Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
SymBio Pharmaceuticals
NCT00908232 COMPLETED Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
Janssen-Cilag International NV
NCT00719901 TERMINATED Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT01078441 TERMINATED Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
National Cancer Institute (NCI)
NCT00911859 COMPLETED A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Janssen Research & Development, LLC
NCT01653418 TERMINATED Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
Washington University School of Medicine
NCT01095757 COMPLETED Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Emory University
NCT00675428 TERMINATED Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
Biogen
NCT02115035 WITHDRAWN A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
University of Arkansas
NCT00691704 COMPLETED Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Cristina Gasparetto
NCT00972959 COMPLETED Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
University of Athens
NCT02114502 WITHDRAWN Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
NCT01096342 COMPLETED Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
NCT01283776 COMPLETED Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation
University of Cologne
NCT00597714 COMPLETED Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
David Rizzieri, MD
NCT00872300 TERMINATED PHA-739358 for the Treatment of Multiple Myeloma
Nerviano Medical Sciences
NCT00872521 COMPLETED A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma
Janssen-Cilag Pty Ltd
NCT01222286 COMPLETED Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Innate Pharma
NCT00743288 COMPLETED Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Oncotherapeutics
NCT00901225 COMPLETED Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Duke University
NCT01105403 COMPLETED Exploratory Study on POL6326 in Stem Cell Mobilization
Polyphor Ltd.
NCT01220375 COMPLETED PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma
Insel Gruppe AG, University Hospital Bern
NCT00847639 COMPLETED Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Center for International Blood and Marrow Transplant Research
NCT00970021 COMPLETED Agaricus Blazei Murill in Patients With Multiple Myeloma
Ullevaal University Hospital
NCT00750815 COMPLETED Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
H. Lee Moffitt Cancer Center and Research Institute
NCT00617591 COMPLETED Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
H. Lee Moffitt Cancer Center and Research Institute
NCT00899353 TERMINATED Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Marshall University
NCT01500161 TERMINATED Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
NCT01168804 COMPLETED Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
Austrian Forum Against Cancer
NCT01037517 COMPLETED Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
CancerCare Manitoba
NCT01232712 COMPLETED A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
Vaxil Therapeutics Ltd.
NCT01617213 TERMINATED Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
University of Virginia
NCT00968396 WITHDRAWN Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
M.D. Anderson Cancer Center
NCT01179490 TERMINATED Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
SymBio Pharmaceuticals
NCT01148108 COMPLETED Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Telik
NCT00823524 COMPLETED Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
NCT01234974 WITHDRAWN IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Milton S. Hershey Medical Center
NCT00882063 COMPLETED Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
Piramal Enterprises Limited
NCT00920855 COMPLETED Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Cephalon
NCT01269203 WITHDRAWN Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
M.D. Anderson Cancer Center
NCT00925821 COMPLETED Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Wuerzburg University Hospital
NCT01492881 WITHDRAWN Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
NCT00760370 COMPLETED Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Vejle Hospital
NCT01116128 TERMINATED Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients
Fondazione EMN Italy Onlus
NCT01010880 COMPLETED Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
Biokine Therapeutics Ltd
NCT00794261 COMPLETED Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
Centre Leon Berard
